Business
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
DUBLIN, February 12, 2026--Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced Alkermes’ completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel’s FDA-approved product, LUMRYZ®, to Alkermes’ commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes’ entry into the sleep medicine market
About this update from Alkermes Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/efe81121528dbcd76d3097efe67a70c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LthD.GJy5qXDtYBvROtaSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/efe81121528dbcd76d3097efe67a70c8","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/38gbdJFR_nOxTspYg.Cj7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/efe81121528dbcd76d3097efe67a70c8","width":1024,"height":512}},"lazy":false},{"type":"text","content":"— Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension —","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"— Expected to be Accretive in 2026 —","length":36,"tagName":"p","attribs":{}},{"type":"text","content":"— Positions the Combined Organization to Accelerate Innovation and Leadership in Development of Treatments for Sleep Disorders and Other Neurological Disorders —","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"DUBLIN, February 12, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced Alkermes’ completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel’s FDA-approved product, LUMRYZ®, to Alkermes’ commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes’ entry into the sleep medicine market and enhances its ability to unlock the full potential of its late-stage development pipeline focused on central disorders of hypersomnolence.","length":679,"tagName":"p"},{"type":"text","content":"The transaction was completed pursuant to an Irish High Court sanctioned scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland. LUMRYZ® (sodium oxybate) for extended-release oral suspension is approved for the treatment of cataplexy or excessive da...